

# Resource Summary Report

Generated by [RRID](#) on Sep 9, 2026

## PA-1

RRID:CVCL\_0479

Type: Cell Line

### Proper Citation

RRID:CVCL\_0479

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_0479](https://web.expasy.org/cellosaurus/CVCL_0479)

**Proper Citation:** RRID:CVCL\_0479

**Description:** Cell line PA-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Female

**Disease:** Ovarian mixed germ cell tumor

**Defining Citation:** [PMID:2653399](#), [PMID:6740333](#), [PMID:6931103](#), [PMID:9290701](#), [PMID:9359923](#), [PMID:9698466](#), [PMID:10567668](#), [PMID:11314036](#), [PMID:11330945](#), [PMID:15677628](#), [PMID:16080959](#), [PMID:20164919](#), [PMID:22710073](#), [PMID:23415752](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:35839778](#)

**Comments:** Caution: TP53 mutation indicated to be at p.Asn239Asp (c.715A>G) in DOI=10.11418/jtca1981.16.3\_173 and PubMed=9359923., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** PA-1

**Synonyms:** PA1, PA I, PAI

**Cross References:** BTO:BTO\_0001591, CLO:CLO\_0008350, EFO:EFO\_0006465, MCCL:MCC:0000377, CLDB:cl3856, CLDB:cl3857, CLDB:cl3858, CLDB:cl3859, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-3610, ATCC:CRL-1572, BCRC:60063, BioSample:SAMN01821586,

BioSample:SAMN03472415, BioSample:SAMN03473209, cancercellines:CVCL\_0479, CCRID:1101HUM-PUMC000021, Cell\_Model\_Passport:SIDM01140, CGH-DB:9358-4, ChEMBL-Cells:ChEMBL3308812, ChEMBL-Targets:ChEMBL614949, CLS:300402, Cosmic:688112, Cosmic:801353, Cosmic:809111, Cosmic:844343, Cosmic:909255, Cosmic:931368, Cosmic:1093560, Cosmic:1305331, Cosmic:1995610, Cosmic-CLP:909255, DepMap:ACH-001374, ECACC:90013101, EGA:EGAS00001000610, EGA:EGAS00001000978, FANTOM5\_SSTAR:10807-111A6, GDSC:909255, GEO:GSM186444, GEO:GSM186445, GEO:GSM784566, GEO:GSM1374804, GEO:GSM1670330, IARC\_TP53:1418, IARC\_TP53:8338, ICLC:HTL97002, IZSLER:BS TCL 179, JCRB:JCRB9061, LINCX\_LDP:LCL-1416, PharmacDB:PA1\_1235\_2019, PRIDE:PXD030304, Progenetix:CVCL\_0479, PubChem\_Cell\_line:CVCL\_0479, RCB:RCB1946, TKG:TKG 0573, Wikidata:Q54937331

**ID:** CVCL\_0479

**Record Creation Time:** 20220427T221407+0000

**Record Last Update:** 20260905T182014+0000

---

## Ratings and Alerts

No rating or validation information has been found for PA-1.

**Warning:** Discontinued: RCB; RCB1946

Caution: TP53 mutation indicated to be at p.Asn239Asp (c.715A>G) in DOI=10.11418/jtca1981.16.3\_173 and PubMed=9359923., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE). **Warning:** Discontinued: TKG; TKG 0573

Caution: TP53 mutation indicated to be at p.Asn239Asp (c.715A>G) in DOI=10.11418/jtca1981.16.3\_173 and PubMed=9359923., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 22 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Pradhan B, et al. (2026) Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer. Cancer research, 86(4), 1073.

Irie K, et al. (2026) Multifaceted role of POU5F1P1 in regulating its parental stem cell gene, POU5F1. *iScience*, 29(4), 115137.

Zhang Z, et al. (2026) A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. *Cell*, 189(10), 2898.

Zhang Z, et al. (2026) A Moderate-Affinity Antibody-Drug Conjugate Targeting B7-H3 Exerts Potent Antitumor Efficacy. *Pharmaceuticals (Basel, Switzerland)*, 19(4).

Surmann H, et al. (2026) Prognostic influence of small leucine-rich proteoglycans on serous ovarian cancer. *Journal of cancer research and clinical oncology*, 152(6).

Ferraresso M, et al. (2025) Replenishing co-downregulated miR-100-5p and miR-125b-5p in malignant germ cell tumors causes growth??inhibition through cell cycle disruption. *Molecular oncology*, 19(4), 1203.

Pai Bellare G, et al. (2025) Targeting Replication Fork Processing Synergizes with PARP Inhibition to Potentiate Lethality in Homologous Recombination Proficient Ovarian Cancers. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 12(18), e2410718.

Nag N, et al. (2024) Metallo-protease Peptidase M84 from *Bacillus altitudinis* induces ROS-dependent apoptosis in ovarian cancer cells by targeting PAR-1. *iScience*, 27(6), 109828.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. *Cell chemical biology*, 31(7), 1247.

Dietrich C, et al. (2024) INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors. *Cancer discovery*, 14(3), 446.

Bandopadhyay S, et al. (2023) Oncogene-mediated nuclear accumulation of lactate promotes epigenetic alterations to induce cancer cell proliferation. *Journal of cellular biochemistry*, 124(4), 495.

Bailey S, et al. (2023) Targeting oncogenic microRNAs from the miR-371~373 and miR-302/367 clusters in malignant germ cell tumours causes growth inhibition through cell cycle disruption. *British journal of cancer*, 129(9), 1451.

Surani AA, et al. (2022) Implications of differential transcription start site selection on chronic myeloid leukemia and prostate cancer cell protein expression. *iScience*, 25(12), 105519.

Do M, et al. (2022) A FZD7-specific Antibody-Drug Conjugate Induces Ovarian Tumor Regression in Preclinical Models. *Molecular cancer therapeutics*, 21(1), 113.

Shonibare Z, et al. (2022) Reciprocal SOX2 regulation by SMAD1-SMAD3 is critical for anoikis resistance and metastasis in cancer. *Cell reports*, 40(4), 111066.

Prasad P, et al. (2021) Glutamine regulates ovarian cancer cell migration and invasion through ETS1. *Heliyon*, 7(5), e07064.

Prasad P, et al. (2021) Glutamine deficiency promotes stemness and chemoresistance in tumor cells through DRP1-induced mitochondrial fragmentation. Cellular and molecular life sciences : CMLS, 78(10), 4821.

Banuelos-Sanchez G, et al. (2019) Synthesis and Characterization of Specific Reverse Transcriptase Inhibitors for Mammalian LINE-1 Retrotransposons. Cell chemical biology, 26(8), 1095.

Yi J, et al. (2019) MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer. EBioMedicine, 43, 225.

Xing YH, et al. (2017) SLERT Regulates DDX21 Rings Associated with Pol I Transcription. Cell, 169(4), 664.